fda ruling on tirzepatide today says shortage of GLP-1 drug is over Important Announcement FDA Update on

References Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK

Younger workers appeared especially influenced by access to these treatments when making career decisions

26, 2026: When Novo Nordisk filed suit against Hims & Hers in early February, the case immediately drew attention as a high-stakes patent fight over semaglutide and what it could mean for the broader multi-billion-dollar market for GLP-1 treatments

Biomedicine & pharmacotherapy prevention of pentylenetetrazole-induced kindling and behavioral comorbidities in mice by levetiracetam combined with the GLP-1 agonist liraglutide : involvement of brain antioxidant and BDNF upregulating properties